SillaJen, Inc.

Sep 16, 2019

SillaJen Defending Position Relating to Recent Sale of Stock by Employee

Aug 02, 2019

SillaJen Announces Conclusions From Interim Futility Analysis Of Phase 3 PHOCUS Trial in HCC

Jun 06, 2019

SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)

Sep 04, 2018

SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

Feb 23, 2018

SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy

Jan 29, 2018

SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy

Jan 22, 2018

SillaJen and ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

Aug 16, 2017

SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's pexastimogene devacirepvec (Pexa-Vec) Oncolytic Immunotherapy

Jul 21, 2017

SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer